Premedication with Enfortumab Vedotin
Premedication is not routinely required before enfortumab vedotin administration according to FDA labeling and pivotal trial protocols, though emerging real-world evidence suggests prophylactic dexamethasone may reduce skin toxicity but potentially compromise survival outcomes.
FDA and Guideline Position
The FDA label for enfortumab vedotin (PADCEV) does not mandate premedication 1. The NCCN guidelines designate enfortumab vedotin plus pembrolizumab as the preferred first-line regimen for advanced urothelial carcinoma based on the EV-302 trial, which did not incorporate routine corticosteroid premedication 2. This aligns with the broader ESMO framework for antibody-drug conjugates like brentuximab vedotin, where premedication is recommended only if a prior infusion reaction occurred 3.
Emerging Real-World Evidence on Corticosteroid Premedication
Recent real-world studies present conflicting data on prophylactic dexamethasone:
Potential Benefits for Toxicity Reduction
- A Japanese multicenter study (n=77) using routine dexamethasone 6.6 mg IV showed manageable cutaneous toxicity with only 3.9% experiencing grade ≥3 skin reactions, compared to historical rates 4
- Another analysis (n=157) demonstrated significantly lower skin adverse events with premedication (10% vs. 62.7%, p<0.001) 5
Critical Survival Concerns
The most concerning finding is that prophylactic corticosteroid premedication was associated with significantly worse overall survival (median OS 10.3 vs. 17.4 months, p=0.008) in the largest comparative study, even after inverse probability of treatment weighting adjustment 5. This remained an independent predictor of reduced survival (HR 1.91, p=0.048) while showing no impact on progression-free survival.
A smaller study (n=28) found no significant differences in efficacy or toxicity with premedication, though trends toward reduced cutaneous events were noted 6.
Clinical Algorithm
For standard patients:
- Do not use routine prophylactic corticosteroids
- Reserve premedication for patients who develop infusion reactions during treatment
- If prior infusion reaction occurred: use dexamethasone 6.6 mg IV, antihistamine, and antipyretic 3
Management of infusion reactions without premedication:
- Grade 1-2: slow or stop infusion, provide symptomatic treatment, resume at slower rate
- Grade 3-4: stop infusion immediately, aggressive symptomatic treatment, consider permanent discontinuation for grade 4 3
Critical Caveats
The survival detriment associated with prophylactic corticosteroids may reflect:
- Immunosuppression interfering with pembrolizumab's mechanism when used in combination
- Selection bias (sicker patients receiving premedication)
- Confounding by indication in retrospective analyses
Given the potential survival compromise and lack of FDA/guideline support for routine premedication, prophylactic corticosteroids should be avoided unless managing documented prior infusion reactions. The trade-off of reduced skin toxicity does not justify potential mortality risk based on current evidence 5.
For patients requiring hemodialysis or with significant comorbidities, EV-pembrolizumab remains feasible without routine premedication, though close monitoring is essential 7, 8.